Evaluation of whole-body tumor burden with 68 Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer.

Autor: Brito AET; Real Nuclear Real Hospital Português de Beneficência em Pernambuco, Av. Gov. Agamenon Magalhães, 4760, Paissandu, Recife, PE, 52010-902, Brazil. aetbrito@gmail.com.; Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, Recife, Brazil. aetbrito@gmail.com., Mourato FA; Real Nuclear Real Hospital Português de Beneficência em Pernambuco, Av. Gov. Agamenon Magalhães, 4760, Paissandu, Recife, PE, 52010-902, Brazil., de Oliveira RPM; Real Nuclear Real Hospital Português de Beneficência em Pernambuco, Av. Gov. Agamenon Magalhães, 4760, Paissandu, Recife, PE, 52010-902, Brazil., Leal ALG; Real Nuclear Real Hospital Português de Beneficência em Pernambuco, Av. Gov. Agamenon Magalhães, 4760, Paissandu, Recife, PE, 52010-902, Brazil., Filho PJA; Real Nuclear Real Hospital Português de Beneficência em Pernambuco, Av. Gov. Agamenon Magalhães, 4760, Paissandu, Recife, PE, 52010-902, Brazil., de Filho JLL; Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, Recife, Brazil.
Jazyk: angličtina
Zdroj: Annals of nuclear medicine [Ann Nucl Med] 2019 May; Vol. 33 (5), pp. 344-350. Date of Electronic Publication: 2019 Feb 11.
DOI: 10.1007/s12149-019-01342-z
Abstrakt: Background: 68 Ga-PSMA-PET has an increasing importance in the evaluation of prostate cancer patients due to its high sensitivity and specificity in identifying neoplastic lesions in the clinical setting of elevated prostate-specific antigen (PSA). The objective of this study was to calculate the whole-body tumor burden using volumetric quantification of lesions detected in 68 Ga-PSMA-PET of prostate cancer patients with biochemical recurrence and correlate these findings with clinical and image parameters.
Methods: Each patient had their 68 Ga-PSMA-PET analyzed for the presence of neoplastic lesions. Their PSA levels and clinical information were recorded. In positive cases, the tumor burden (TL-PSMA) was calculated with a semi-automatic software and manually, and the results are analyzed and tested.
Results: We analyzed 100 prostate cancer patients, mean age of 69.9 ± 9.7 years and a median PSA of 1.73 ng/dL. 68 Ga-PSMA-PET identified neoplastic lesions in 72% of them. The median TL-PSMA was 55.95 ml (1.1-28,080 ml). TL-PSMA and PSA were strongly correlated (rho = 0.71, p < 0.0001, 95% CI 0.60-0.80). TL-PSMA and PSA levels groups had a significant correlation and TL-PSMA and Gleason score were independent variables associated with PSA levels (p < 0.05).
Conclusion: TL-PSMA strongly and independently correlates with PSA levels in prostate cancer patients and could be used as a biomarker to separate them into groups with high or low tumor burden, instead of considering only the number of lesions.
Databáze: MEDLINE
Externí odkaz: